Description
Function：
Dabigatran etexilate mesylate is a direct thrombin inhibitor used in clinical practice and a new type of oral anticoagulant. Its mechanism of action is to inhibit the formation of fibrin through reversible and strong competition to bind to the specific binding site of thrombin fibrin, thereby inhibiting the formation of thrombus.
Dabigatran etexilate mesylate is a direct thrombin inhibitor used in clinical practice and a new type of oral anticoagulant. Its mechanism of action is to inhibit the formation of fibrin through reversible and strong competition to bind to the specific binding site of thrombin fibrin, thereby inhibiting the formation of thrombus.
Dabigatran etexilate mesylate is a raw material for the blood system; an anticoagulant drug; it can be used in patients with non-valvular atrial fibrillation to reduce the risk of stroke and systemic embolism; Chemicalbook dabigatran etexilate is a new type of synthetic The direct thrombin inhibitor is a prodrug of dabigatran and is a non-peptide thrombin inhibitor.
| Product name | Dabigatran Etexilate Mesylate | ||
| Reference | USDMF standard | ||
| Test Items | Results | ||
| Residual solvents (GC) | Ethanol≤5000ppm | N.D | |
| Ethyl acetate≤5000ppm | <LOQ(50ppm) | ||
| Tetrahydrofuran≤720ppm | N.D | ||
| Acetone≤5000ppm | N.D | ||
| Dichloromethane≤600ppm | N.D | ||
| Acetic acid≤5000ppm | <LOQ(150ppm) | ||
| 1 -Hexanol ≤1500ppm | <LOQ(151ppm) | ||
| Residual Reagents(GC) | Triethylamine≤320ppm | N.D | |
| Polymorphism | Comply with Form I | Conforms | |
| Residual Reagents (ICP- OES) | Palladium≤10ppm | <LOD(0.4ppm) | |
| Conclusion | Complies with USDMF standard | ||
